Merck rebrands animal division
Merck’s animal division, which will be known as MSD Animal Health outside Canada and the US, focuses on research, manufacturing, development and sale of veterinary drugs and vaccines.
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).